Diabetes mellitus alters the effect of peptide and protein ligands on membrane fluidity of blood platelets.
The increased nonenzymatic glycosylation of platelet membrane proteins has been suggested to underlie platelet hypersensitivity in diabetes and the relationship of this to the reduced membrane lipid fluidity has been reported. As the modulation in membrane fluidity may determine the degree of accessibility of membrane receptors, the consequent alterations in membrane lipid-protein interactions in diabetes mellitus may also underlie the differentiated effects of various thrombotic and fibrinolytic agents on platelet membrane lipid bilayer. In the present study we employed electron paramagnetic resonance and fluorescence spectroscopy to explore the ligand-induced platelet membrane fluidity changes in diabetic state, i.e. under conditions when the membrane architecture is considerably altered. The yield of the excimer formation of pyrenemaleimide (PM), which depends directly upon the collisional rate and distances between molecules, was elevated in diabetic platelet membranes, thus pointing to the occurrence of some constraints in the structure/conformation of platelet membrane proteins in diabetes mellitus. Such an immobilization of PM was accompanied by the significant elevation in membrane protein glycation in diabetic platelets. The effects of various interacting ligands on platelet membrane fluidity were significantly lower in diabetic platelets, and the differences were much more distinct at the lower depths of a lipid bilayer. Nevertheless, the alterations in membrane lipid fluidity observed upon the interaction of a given ligand occurred with an approximately equal frequency in control and diabetic platelets. Moreover, the probability that these alterations were less profound in diabetic platelets was the same for all types of ligands studied. In diabetic patients the interaction of RGDS and tissue-type plasminogen activator with platelet membranes resulted in much smaller reductions of the h+/h0 parameters in 5-DOXYL-Ste acid-labelled platelets, thus indicating a lesser rigidization of membrane lipid bilayer in diabetes. Likewise, the fluidizing effect of both fibrinogen itself and fibrinogen-derived peptides containing gamma-chain carboxy-terminal sequence H-12-V was less pronounced in diabetic platelet membranes.
Watala
C
C
Laboratory of Haemostasis and Haemostatic Disorders, Medical University of Lódź, Poland.
Gwoździński
K
K
Pluskota
E
E
Pietrucha
T
T
Walkowiak
B
B
Trojanowski
Z
Z
Cierniewski
C S
CS
D000328:Adult; D000595:Amino Acid Sequence; D001792:Blood Platelets / Q000378:metabolism* / Q000648:ultrastructure; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004578:Electron Spin Resonance Spectroscopy; D005260:Female; D006801:Humans; D008051:Lipid Bilayers; D008297:Male; D008560:Membrane Fluidity / Q000502:physiology*; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D008969:Molecular Sequence Data; D010455:Peptides / Q000097:blood*
D008051:Lipid Bilayers; D008565:Membrane Proteins; D010455:Peptides